Johnson & Johnson (JNJ) Shares Bought by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. boosted its position in Johnson & Johnson (NYSE:JNJ) by 13.7% during the 4th quarter, HoldingsChannel reports. The firm owned 153,470 shares of the company’s stock after purchasing an additional 18,540 shares during the quarter. Johnson & Johnson accounts for about 2.4% of Stock Yards Bank & Trust Co.’s holdings, making the stock its 8th largest holding. Stock Yards Bank & Trust Co.’s holdings in Johnson & Johnson were worth $21,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Harding Loevner LP bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after buying an additional 200 shares during the last quarter. IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares during the last quarter. Mountain Capital Investment Advisors Inc bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $124,000. Finally, Lenox Wealth Management Inc. increased its holdings in shares of Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares during the last quarter. Institutional investors and hedge funds own 67.21% of the company’s stock.

How to Become a New Pot Stock Millionaire

A number of brokerages have recently commented on JNJ. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target on the stock in a report on Thursday, January 11th. Jefferies Group set a $161.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. BMO Capital Markets increased their price target on shares of Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $146.06.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.19% of the stock is owned by company insiders.

Shares of JNJ stock opened at $125.10 on Friday. The stock has a market cap of $341,748.06, a price-to-earnings ratio of 320.77, a price-to-earnings-growth ratio of 2.03 and a beta of 0.77. Johnson & Johnson has a twelve month low of $120.95 and a twelve month high of $148.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 EPS. equities analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 861.54%.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Bought by Stock Yards Bank & Trust Co.” was posted by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3295809/johnson-johnson-jnj-shares-bought-by-stock-yards-bank-trust-co.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Republic Services  Expected to Announce Quarterly Sales of $2.41 Billion
Republic Services Expected to Announce Quarterly Sales of $2.41 Billion
Analyzing Costco Wholesale  and Its Rivals
Analyzing Costco Wholesale and Its Rivals
Reviewing CURO Group  and Its Peers
Reviewing CURO Group and Its Peers
PRGX Global  vs. Forrester Research  Financial Comparison
PRGX Global vs. Forrester Research Financial Comparison
Care.com  vs. Weight Watchers  Head-To-Head Survey
Care.com vs. Weight Watchers Head-To-Head Survey
SpreadCoin  Achieves Market Capitalization of $6.02 Million
SpreadCoin Achieves Market Capitalization of $6.02 Million


© 2006-2018 Ticker Report. Google+.